https://www.selleckchem.com/products/ulk-101.html
86.3% (69/80, P = 0.815) and 91.9% (68/74) vs. 91.8% (67/73, P = 0.98 as first-line therapies; 83.3% (25/3 vs. 83.3% (25/30, P = 1) and 89.3% (25/28) vs. 88.9% (24/27, P = 1) as second-line therapies. Symptom improvement rates were 96.1% and 97.0% for IDFA and IDFB (P = 1). The adverse event rates were 10.9% in IDFA and 14.5% in IDFB groups (P = 0.418). Nausea occurred frequently in IDFB than IDFA (1.8% vs. 8.2%, P = 0.03. Smoking and sharing utensils significantly affected the efficacy. Allicin-containing quadruple therapy might
Like
Comment
Share
